Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193586 XXXXXXXX LIVE 1 Common Stock 01/23/2026 false 0001626971 221015100 Corvus Pharmaceuticals, Inc. 901 Gateway Boulevard Third Floor South San Francisco CA 94080 Adams Street Partners (312) 553-7890 One North Wacker Drive, Suite 2700 Chicago IL 60606 0001193586 N Adams Street Partners, LLC OO N DE 3275616.00 0.00 3275616.00 0.00 3275616.00 N 3.9 IA Comment to Rows 7, 9, 11: Represents 236,128 shares held directly by Adams Street Venture/Growth Fund VI LP ("AS VGVI"), 694,854 shares held by Adams Street 2011 Direct Fund LP ("AS 2011"), 715,361 shares held by Adams Street 2012 Direct Fund LP ("AS 2012"), 541,133 shares held by Adams Street 2013 Direct Fund LP ("AS 2013"), 736,033 shares held by Adams Street 2014 Direct Fund LP ("AS 2014"), 69,864 shares held directly by Adams Street 2015 Direct Venture/Growth Fund LP ("AS 2015"), 67,769 shares held directly by Adams Street 2016 Direct Venture/Growth Fund LP ("AS 2016"), 87,668 shares held directly by Adams Street 2017 Direct Venture/Growth Fund LP ("AS 2017"), and 126,806 shares held directly by Adams Street 2018 Direct Venture/Growth Fund LP ("AS 2018"). Adams Street Partners, LLC, as the managing member of the general partner of the general partner of each of AS VGVI, AS 2011, AS 2012, AS 2013, AS 2014, AS 2015, AS 2016, AS 2017, and AS 2018 may be deemed to beneficially own the shares held by each of such funds. Thomas S. Bremner, Jeffrey T. Diehl, Brian Dudley, Elisha P. Gould, Robin Murray and Fred Wang, each of whom is a partner of Adams Street Partners, LLC (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by these funds. Adams Street Partners, LLC and Thomas S. Bremner, Jeffrey T. Diehl, Elisha P. Gould, Robin Murray and Fred Wang disclaim beneficial ownership of the shares held by each of AS VGVI, AS 2011, AS 2012, AS 2013, AS 2014, AS 2015, AS 2016, AS 2017 and AS 2018 except to the extent of their pecuniary interest therein. Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering (as defined in Item 1) as set forth in the Issuer's Rule 424(b)(5) Prospectus filed with the SEC on January 23, 2026 (the "Prospectus") and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Issuer's Current Report on Form 8-K filed with the SEC on January 23, 2026 (the "Current Report"). 0001507788 N Adams Street 2011 Direct Fund LP OO N DE 694854.00 0.00 694854.00 0.00 694854.00 N 0.8 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001537362 N Adams Street 2012 Direct Fund LP OO N DE 715361.00 0.00 715361.00 0.00 715361.00 N 0.9 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001564720 N Adams Street 2013 Direct Fund LP OO N DE 541133.00 0.00 541133.00 0.00 541133.00 N 0.6 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001594043 N Adams Street 2014 Direct Fund LP OO N DE 736033.00 0.00 736033.00 0.00 736033.00 N 0.9 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001623365 N Adams Street 2015 Direct Venture/Growth Fund LP OO N DE 69864.00 0.00 69864.00 0.00 69864.00 N 0.1 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001653592 N Adams Street 2016 Direct Venture/Growth Fund LP OO N DE 67769.00 0.00 67769.00 0.00 67769.00 N 0.1 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001685559 N Adams Street 2017 Direct Venture/Growth Fund LP OO N DE 87668.00 0.00 87668.00 0.00 87668.00 N 0.1 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001720383 N Adams Street 2018 Direct Venture/Growth Fund LP OO N DE 126806.00 0.00 126806.00 0.00 126806.00 N 0.2 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. 0001623687 N Adams Street Venture/Growth Fund VI LP OO N DE 236128.00 0.00 236128.00 0.00 236128.00 N 0.3 PN Comment to Row 13: Based on 83,767,650 shares Common Stock outstanding as of January 23, 2026, which amount includes (i) 82,582,549 shares Common Stock following completion of the Offering as set forth in the Prospectus and (ii) 1,185,101 shares of Common Stock purchased by the underwriters in the Offering upon the exercise of their option to purchase such shares, as described in the Current Report. Common Stock Corvus Pharmaceuticals, Inc. 901 Gateway Boulevard Third Floor South San Francisco CA 94080 This Amendment No. 1 ("Amendment No. 1") to Schedule 13D relates to the Common Stock, $0.0001 par value per share ("Common Stock"), of Corvus Pharmaceuticals, Inc., a Delaware corporation ("Corvus" or "Issuer"). The original Schedule 13D was filed with the Securities Exchange Commission ("SEC") on March 21, 2018 (the "Schedule 13D"). On January 23, 2026, the Issuer completed an underwritten public offering of 7,900,677 shares of Common Stock at a price of $22.15 per share and sold an additional 1,185,101 shares of Common Stock upon the underwriters' exercise of its option to purchase additional shares (the "Offering"). This Amendment No. 1 is being filed to reflect a change in the percentage of shares of Common Stock previously reported by the Reporting Persons solely as a result of a change in the outstanding shares of Common Stock as reported by the Issuer. This Schedule 13D is being jointly filed by Adams Street Partners, LLC, Adams Street 2011 Direct Fund LP, Adams Street 2012 Direct Fund LP, Adams Street 2013 Direct Fund LP, Adams Street 2014 Direct Fund LP, Adams Street 2015 Direct Venture/Growth Fund LP, Adams Street 2016 Direct Venture/Growth Fund LP, Adams Street 2017 Direct Venture/Growth Fund LP, Adams Street 2018 Direct Venture/Growth Fund LP and Adams Street Venture/Growth Fund VI LP. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the aforementioned funds and may be deemed to beneficially own the shares held by them. The address of the principal offices of each of the filing entities is One North Wacker Drive, Suite 2700, Chicago, Illinois, 60606. The principal occupation of each of the persons set forth on Schedule I hereto is the venture capital and growth equity investment business. The information set forth in Schedule I hereto is incorporated herein by reference. None of the Reporting Persons have, and to the best of each Reporting Person's knowledge, during the last five years, each of the Reporting Persons has not, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). None of the Reporting Persons have, and to the best of each Reporting Person's knowledge, during the last five years, each of the Reporting Persons has not, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activity subject to, federal or state securities laws or finding any violations with respect to such laws. Each of the Reporting Persons is a United States citizen. Item 5(a) of the Schedule 13D is hereby amended and restated in its entirety as follows: Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Item 5(b) of the Schedule 13D is hereby amended and restated in its entirety as follows: Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person. Item 5(c) of the Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Persons have not effected any transaction in the Common Stock of the Issuer during the past 60 days. Under certain circumstances set forth in the limited partnership agreements of the Reporting Persons, the general partner and limited partners of the reporting persons may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entities of which they are a partner. Item 5(e) of the Schedule 13D is hereby amended and restated in its entirety as follows: January 23, 2026. Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows: SCHEDULE I. EXHIBIT A. Form of Indemnification Agreement for Directors and Officers, incorporated herein by reference to Exhibit 10.4 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 1, 2018. EXHIBIT B. Amended and Restated Investors' Rights Agreement, dated September 16, 2015, by and among Corvus Pharmaceuticals, Inc. and the investors listed therein, incorporated herein by reference to Exhibit 4.3 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 1, 2018. EXHIBIT C. Joint Filing Agreement dated March 21, 2018 by and between the Reporting Persons, incorporated by reference to Exhibit C of the Schedule 13D. Adams Street Partners, LLC /s/ Sara Robinson Dasse Sara Robinson Dasse, Executive Vice President 02/05/2026 Adams Street 2011 Direct Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2011 Dir. Mgmt. LLC, the GP of ASP 2011 Dir. Mgmt. LP, the GP of Adams Street 2011 Dir. Fund LP 02/05/2026 Adams Street 2012 Direct Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2012 Dir. Mgmt. LLC, the GP of ASP 2012 Dir. Mgmt. LP, the GP of Adams Street 2012 Dir. Fund LP 02/05/2026 Adams Street 2013 Direct Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2013 Dir. Mgmt. LLC, the GP of ASP 2013 Dir. Mgmt. LP, the GP of Adams Street 2013 Dir. Fund LP 02/05/2026 Adams Street 2014 Direct Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2014 Dir. Mgmt. LLC, the GP of ASP 2014 Dir. Mgmt. LP, the GP of Adams Street 2014 Dir. Fund LP 02/05/2026 Adams Street 2015 Direct Venture/Growth Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2015 Dir. Mgmt. LLC, the GP of ASP 2015 Dir. Mgmt. LP, the GP of Adams Street 2015 Dir. V/G Fund LP 02/05/2026 Adams Street 2016 Direct Venture/Growth Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2016 Dir. Mgmt. LLC, the GP of ASP 2016 Dir. Mgmt. LP, the GP of Adams Street 2016 Dir. V/G Fund LP 02/05/2026 Adams Street 2017 Direct Venture/Growth Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2017 Dir. Mgmt. LLC, the GP of ASP 2017 Dir. Mgmt. LP, the GP of Adams Street 2017 Dir. V/G Fund LP 02/05/2026 Adams Street 2018 Direct Venture/Growth Fund LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP 2018 Dir. Mgmt. LLC, the GP of ASP 2018 Dir. Mgmt. LP, the GP of Adams Street 2018 Dir. V/G Fund LP 02/05/2026 Adams Street Venture/Growth Fund VI LP /s/ Sara Robinson Dasse Sara R. Dasse/EVP ASP LLC, the Mng. Member of ASP VG Mgmt. VI LLC, the GP of ASP VG Mgmt. VI LP, the GP of Adams Street V/G VI LP 02/05/2026